• 中文 Chinese
  • 英文 English
  • Site Map
  • About Us
    • Company
    • Board
    • Management
    • Partnerships
    • Activities
  • Pipeline
    • Ibalizumab (TMB-355) Intravenous Infusion
    • Ibalizumab (TMB-355) Intravenous Push
    • Ibalizumab (TMB-355) Intramuscular Injection
    • TMB-365
    • TMB-365/TMB-380 (TMB-365 and TMB-380 combination)
  • CDMO Service
    • Overview
    • Our advantage
    • Contract Development & Manufacturing Service
    • Our services
  • News
    • Recent News
    • Announcement
    • Events
    • Biotech Column
  • Investor Relations
    • Company
      • Company Profile
      • Company Presentation
    • Corporate Governance
      • Organization
      • Board
      • Committee
      • Internal Audit
      • Major Internal Policies
    • Financials
      • Monthly Revenue
      • Financial Reports
    • Shareholders' Services
      • Major Shareholders
      • Dividend Information
      • Investor and Stock Information
      • Shareholder's Meeting
  • Contact Us
  • 中文 Chinese
  • 英文 English
  • Site Map
Latest News   

2023-03-10      Taimed is exhibiting at the 2023 Bio-Europe Spring

TaiMed Biologics Inc.
4147   |   Email Alert   |   Disclaime
TEL +886-2-2658-0058  |  FAX +886-2-2658-6058

3F.,NO.607,Ruiguang Rd.,Neihu Dist.,
Taipei City 11492,Taiwan(R.O.C.)
Copyright © 2017 TaiMed Biologics Inc.
All Rights Reserved.